CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 337 · Search date 2026-07-11 · Methodology v0.6

Gastrodia elata extract,
does it really help with Improvement of memory and cognitive function?

30-Second Summary
C
Evidence Grade C · 52 · Safety acceptable
A recent positive cognitive RCT exists, but earlier overall-population null findings and selective endpoints remain
What the
research shows
A 2025 RCT of Gastrodia hot-water extract at 500 mg in 100 participants improved ADAS-cog and K-MMSE. A 2022 trial was null in the overall population and positive only in the BDNF Val/Met subgroup, while a 50-person 2013 trial had multiple endpoints and high attrition. HX106 combines Gastrodia with Salvia, longan, and Liriope and is not standalone evidence. Conflicting positive and null findings result in C.
What the
ads claim
Advertising may describe memory enhancement, brain activation, and dementia prevention, while the direct evidence concerns 12-week changes in cognitive tests among middle-aged and older adults.
*

Useful facts when choosing a product

  • The 2025 trial used tablets providing 500 mg/day of Gastrodia extract for 12 weeks.
  • Gastrodia powder, hot-water tea, and standardized extracts differ in manufacturing and constituent content.
  • Positive and null findings were reported across multiple cognitive tests.
  • No serious adverse-event signal was reported in the 12-week trials.
Gap Measurement · Verdict 337 · C 52
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Jun 2025 administered 500 mg/day of Gastrodia hot-water extract for 12 weeks to 100 adults and reported improvements in ADAS-cog and K-MMSE. The Jung 2022 pilot was null for cognitive tests in the overall population and positive only in the BDNF Val/Met subgroup. Kim 2013 tested 50 participants, reported selected positives among many cognitive endpoints, and had high attrition. HX106 is a four-ingredient combination of Gastrodia, Salvia, longan, and Liriope and is excluded as standalone Gastrodia evidence.

02

Why this is classified as C (52)

The positive ADAS-cog and K-MMSE results in the 2025 standalone hot-water-extract trial are direct signals. They conflict with the 2022 overall-population null result and Val/Met-only finding and the multiple-endpoint, high-attrition 2013 trial; HX106 is not standalone evidence. The result is C with 52 points.

Counterpoint. A 12-week ADAS-cog signal remains for the recent standardized extract; this judgment does not dismiss that signal or extend it to long-term clinical outcomes.

Rejudgment record. Reassessment (cross-check reflected) — A 2025 100-person RCT of 500 mg Gastrodia hot-water extract was positive for ADAS-cog and K-MMSE, but a 2022 trial was null overall and positive only in the Val/Met subgroup, a 2013 50-person study had multiple endpoints and high attrition, and the four-ingredient HX106 is not standalone evidence

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Kim WC et al. 2013Twelve-week double-blind comparative clinical trial50UnknownK-DRS, MMSE-K, Digit Span, letter fluency, word list, and Trail Making TestSelected K-DRS domains, MMSE-K, letter fluency, and word recognition improved, while Digit Span and Trail Making Test did not differ.Supportive, small
Jung SJ et al. 2022Twelve-week randomized double-blind placebo-controlled pilotUnknown; no competing interest reportedCognitive tests, BDNF, CRP, and BDNF genotype subgroupCognitive tests did not differ in the overall population; only verbal and visual recognition in the Val/Met subgroup was positive.Key, overall population null
Jun H et al. 2025Twelve-week randomized double-blind placebo-controlled trial98Not identified in the public abstract; linked to development for individual recognitionADAS-cog primary endpoint, K-MMSE, BDNF, amyloid beta, and total antioxidant statusADAS-cog, K-MMSE, BDNF, and total antioxidant status improved, while amyloid beta did not.Key, recent positive trial
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-11).

Kim WC, Jeong JG, Kim JS, Kim KO. The Verify of Memory Improvement by Gastrodia Elata Blume. J of Oriental Neuropsychiatry. 2013;24(1):27-43. DOI: 10.7231/jon.2013.24.1.027.
checked
Jung SJ, Jung ES, Cui Y, Nguyen TB, Ha KC, Baek HI, Han SK, Lee SO, Chae SW, Chung YC. Effects of Gastrodia elata Blume on Cognitive Function Improvement: A 12 Weeks, Randomized, Double-Blind, Placebo-Controlled Pilot Study. Int J Pharmacol. 2022;18:765-774. DOI: 10.3923/ijp.2022.765.774.
checked
Jun H, Lee J, Park BO, Kim RW, Leem J, Kwon KB. Gastrodia elata blume (Gastrodiae Rhizoma, Tianma) extract for cognitive enhancement in middle-aged adults with normal or mild impairment: A randomized, double-blind, placebo-controlled clinical trial. J Funct Foods. 2025;131:106942. DOI: 10.1016/j.jff.2025.106942.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

Gastrodia elata extract x improvement of memory and cognitive function Evidence Grade C card
[Chamgap] Gastrodia elata extract x improvement of memory and cognitive function — Evidence Grade C·52. 3 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/cognition/gastrodia-elata-memory-cognition/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.